ARCHIVES

In Sign-Off Of Two Orphan Drugs, ODAC Leaves Efficacy Interpretation To Docs

This article is from The Cancer Letter archive.

Vol. 24 No. 45 | November 27, 1998

Download PDF Visit The Full Archive

Related Articles

Penn Begins Clinical Trial Of A Vaccine For Breast Cancer Based On Telomerase

February 27, 2004

NCI awards $42 million for prevention trials consortium.

December 5, 2003

Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease

June 29, 2012

Study Finds Up To 12 Percent Of Specimens Misdiagnosed

October 28, 2005

Mammography Hazard In ACS-NCI Screening Charged

October 17, 1975

Committee Approves Concepts For Studies In Special Populations

December 11, 1987